EMA Domperidone Guide Could Hurt Xian Janssen Sales In China
This article was originally published in PharmAsia News
The guide suggested by the European Medicine Agency limiting domperidone, marketed under Motilium by Johnson & Johnson to treat nausea and vomiting would cause sale losses of up to 80% in China where it is more widely used for stomach diseases, says an OTC commercial expert.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.